Pharmacovigilance is the process of monitoring the safety of medicines after they have been approved and are on the market. The future of pharmacovigilance is likely to involve a number of advancements and changes in the way that the safety of medications is monitored and evaluated.

One area of focus is likely to be the use of big data and artificial intelligence (AI) to identify potential safety concerns more quickly and accurately. With the increasing amount of data generated by electronic health records, social media, and other sources, machine learning algorithms can be trained to identify patterns that might indicate a safety problem.

Another area that is likely to see growth is the use of "real-world" data to supplement the information gathered in clinical trials. With the rise of wearables and other digital health technologies, it may be possible to collect more detailed and objective data on how people are using and responding to medications.

Another trend is the use of blockchain technology to ensure the integrity and traceability of the data. This would ensure that any manipulation or erasure of data would be easily traceable and preventable.

Finally, more active collaboration and information sharing between pharmaceutical companies, regulators, and healthcare providers is expected to be a key area of focus in the future of pharmacovigilance. This will help to ensure that any potential safety issues are identified and addressed as quickly as possible.

Overall, the future of pharmacovigilance is likely to be characterized by an increased use of data and technology, more collaboration, and a greater emphasis on transparency and accountability.

This website uses its own and third-party cookies to improve your experience, some of which are essential for certain parts of the website to function correctly. Learn more in the Cookies Policy.